Gemma M. Matthys

Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study

C. Stringer, M. Friedlander, D. Rischin, 2007 .

Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive unresectable or metastatic melanoma (MM).

G. Linette, J. Wolchok, J. Sosman, 2014 .

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.

M. Friedlander, C. Stringer, D. Rischin, 2010, Gynecologic oncology.

Pharmacokinetics and Pharmacodynamics Clinical Pharmacokinetics, Platelet Response, and Safety of Eltrombopag at Supratherapeutic Doses of up to 200 mg Once Daily in Healthy Volunteers

B. Peng, C. Bowen, J. Park, 2011, Journal of clinical pharmacology.

Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects.

B. Peng, C. Bowen, J. Park, 2010, British journal of clinical pharmacology.

Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours

J. Schellens, A. Robidoux, L. Cartee, 2014, Investigational New Drugs.